Cyprus Mail
Health

Covid -19 vaccine makers start work on Omicron-tailored shots

a vial and a syringe are seen in front of a displayed eu flag and words "omicron sars cov 2" in this illustration taken
REUTERS/Dado Ruvic/Illustration

BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target Omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on Monday.

The variant’s emergence has triggered a strong global response as countries worried that it could spread fast even in vaccinated populations impose travel curbs and other restrictions.

BioNTech SE said it had started work on a vaccine tailored to Omicron, along with partner Pfizer.

Meanwhile, Moderna Inc said it could take months to begin shipping such a vaccine, Chief Executive Officer Stéphane Bancel told CNBC.

Bancel said the effectiveness of existing COVID-19 vaccines against the variant was currently not known, adding there should be more clarity in about two weeks.

Johnson & Johnson is also evaluating the effectiveness of its COVID-19 vaccine against Omicron, while also pursuing a vaccine specific to the variant.

“We have begun work to design and develop a new vaccine against Omicron and will rapidly progress it into clinical studies if needed,” said Mathai Mammen, global head of research for J&J’s pharmaceuticals unit.

A top South African infectious disease expert said Omicron appears to be more transmissible than previous variants, including to people with immunity from vaccination or prior infection.

Related Posts

Hadjipantela defends ministry’s procedures in face of spat with HIO

Jean Christou

Seven contacts of first monkeypox case vaccinated on Sunday

Staff Reporter

Our View: New ‘health emergency’ mustn’t degenerate into another Covid

CM: Our View

Two more cases of monkeypox, vaccines arrive (Update 2)

Kyriacos Nicolaou

‘HIO has brought Gesy to brink of collapse’

Sarah Ktisti

‘Early signs’ monkeypox outbreak plateauing in UK, health authority says

Reuters News Service